Holen Sie sich die Stockscreener-App
1.985
1.24%
-0.025
Schlusskurs vom Vortag:
$2.01
Offen:
$1.96
24-Stunden-Volumen:
57,338
Relative Volume:
0.89
Marktkapitalisierung:
$9.10M
Einnahmen:
$468.00K
Nettoeinkommen (Verlust:
$-10.34M
KGV:
-0.2816
EPS:
-7.05
Netto-Cashflow:
$-8.94M
1W Leistung:
-21.85%
1M Leistung:
-24.24%
6M Leistung:
-26.21%
1J Leistung:
-65.67%
1-Tages-Spanne:
$1.74
$2.02
1-Wochen-Bereich:
$1.74
$2.60
52-Wochen-Spanne:
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
Firmenname
Biocardia Inc
Sektor
Branche
Telefon
650-226-0123
Adresse
320 SOQUEL WAY, SUNNYVALE, CA
Vergleichen Sie BCDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
19.28 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1501 | 337.66M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.32 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.26 | 139.95M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
9.71 | 137.23M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-16 | Herabstufung | Dawson James | Buy → Neutral |
Biocardia Inc Aktie (BCDA) Neueste Nachrichten
Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com South Africa
Trial Results Show Autologous Cell Therapy Improves Survival, QOL and Reduces Cardiac Events in Distressed Heart Failure Patients - Diagnostic and Interventional Cardiology
Financial Analysis: BioCardia Inc (BCDA)’s Ratios Unveil Key Insights - DWinneX
BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Call Transcript - Insider Monkey
BioCardia Clarifies Timing for CardiAMP-HF Results Call - MSN
BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... - Yahoo Finance
ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains - Yahoo
BioCardia reports promising two-year CardiAMP trial results By Investing.com - Investing.com South Africa
Earnings call transcript: BioCardia Q4 2024 sees reduced expenses, stock down - Investing.com India
BioCardia Phase 3 CARDIAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years - HMP Global Learning Network
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - The Manila Times
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - Barchart.com
Critical CardiAMP-HF 2-Year Data Reveal: Key Findings Presentation Today - Stock Titan
BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint - MarketScreener
BioCardia reports promising two-year CardiAMP trial results - Investing.com
BioCardia Reports Positive Phase 3 CardiAMP-HF Results - TipRanks
Breakthrough Heart Failure Treatment Shows 47% Death Risk Reduction in Phase 3 Trial - Stock Titan
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Beating Heart Patch Market Projected To Witness Substantial - openPR.com
BioCardia Reports 2024 Business Highlights and Financial Results - The Manila Times
BioCardia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings - GuruFocus
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - The Manila Times
BioCardia, Inc. to Report 2024 Financial Results and Host Conference Call Following CardiAMP-HF Trial Presentation - Nasdaq
SBA Communications (SBAC) Gets a Buy from Barclays - The Globe and Mail
BioCardia Sets Major March Catalyst: 2024 Earnings Plus Pivotal Heart Trial Data - Stock Titan
MindMed Appoints Matt Wiley as Chief Commercial Officer - The Globe and Mail
Reviewing BioCardia (NASDAQ:BCDA) & Moderna (NASDAQ:MRNA) - Defense World
UiPath (PATH) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
BioCardia secures new Japanese patent for heart therapy delivery By Investing.com - Investing.com Australia
BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System -March 10, 2025 at 02:53 pm EDT - Marketscreener.com
BioCardia secures new Japanese patent for heart therapy delivery - Investing.com
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - The Manila Times
BioCardia announces Japanese patent for Helix system - TipRanks
BioCardia Wins Patent Protection in Japan for Novel Heart Therapy System - StockTitan
BioCardia director Simon Stertzer acquires $2,450 in stock By Investing.com - Investing.com Australia
BioCardia director Simon Stertzer acquires $2,450 in stock - Investing.com
Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia - TipRanks
Biocardia director Simon Stertzer acquires $88,064 in stock By Investing.com - Investing.com South Africa
Biocardia director Simon Stertzer acquires $88,064 in stock - Investing.com India
Biocardia CEO Peter Altman buys $1,055 in company stock - Investing.com
BioCardia Announces Primary Data Freeze For CardiAMP HF Phase 3 Trial For ACC 2025 Presentation - Nasdaq
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - The Manila Times
BioCardia wraps up Phase 3 CardiAMP HF study data - Investing.com India
BioCardia finishes data freezing in heart failure therapy study for presentation - TipRanks
Finanzdaten der Biocardia Inc-Aktie (BCDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocardia Inc-Aktie (BCDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Apr 02 '25 |
Buy |
2.23 |
500 |
1,115 |
110,120 |
| Altman Peter | President and CEO |
Apr 03 '25 |
Buy |
2.24 |
1,200 |
2,688 |
109,620 |
| STERTZER SIMON H | Director |
Mar 05 '25 |
Buy |
2.45 |
1,000 |
2,450 |
57,138 |
| STERTZER SIMON H | Director |
Mar 03 '25 |
Buy |
2.30 |
22,753 |
52,332 |
40,602 |
| STERTZER SIMON H | Director |
Mar 04 '25 |
Buy |
2.30 |
15,536 |
35,733 |
56,138 |
| Altman Peter | President and CEO |
Mar 03 '25 |
Buy |
2.11 |
500 |
1,055 |
108,420 |
| Altman Peter | President and CEO |
Feb 07 '25 |
Buy |
2.48 |
600 |
1,488 |
107,920 |
| Altman Peter | President and CEO |
Jan 29 '25 |
Buy |
2.40 |
500 |
1,200 |
107,081 |
| Altman Peter | President and CEO |
Jan 30 '25 |
Buy |
2.38 |
239 |
569 |
107,320 |
| Altman Peter | President and CEO |
Dec 23 '24 |
Buy |
2.06 |
1,000 |
2,060 |
106,581 |
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):